Abattis Bioceuticals, Corp. (ATTBF)

38d6d7dAbattis Bioceuticals Corporation, a specialty biotechnology company, strives to be a leader in the growing, testing, and distribution of cannabis in North America for medicinal and adult use. The development stage company develops proprietary health and wellness solutions that aim to address chronic diseases and illnesses in humans and animals through both bacterial and anti-viral formulas.

Through its wide network of partners and subsidiaries, Abattis has developed a unique grow, dry, extract, refine, sell or GDERS strategy that encompasses the whole industry supply chain from seed to sale. It is a company that has capabilities through its wholly owned subsidiaries for licensing, cultivating, and marketing of proprietary ingredients, patented equipment, bio-similar compounds, and consulting services to medicinal markets throughout North America.

Abattis is positioned to capitalize on the fast growing trend of marijuana legalization by partnering and supplying companies with its vertical cultivation systems, extraction technology and equipment, and strategic marketing support to licensed growers. The company also has a widespread pipeline of Intellectual Property and high-quality products for the expanding botanical drug market.

Among Abattis’ companies are Biocube Green Grow Systems CorporationBiocell Labs, Inc., North America Bioextracts, Northern Vine Canada, Inc., and iJuana Cannabis, Inc. Abattis’ list of partners include PhytaLab, Experion Bio Technologies, Inc., and Instant Payment Systems.

Abattis adheres to the strict standard operating protocols, following laws pertaining to cultivating, testing, and selling of cannabis in both the United States and Canada.

Yahoo! Finance: ATTBF News

Latest Financial News for ATTBF

Abattis Provides Update on Trading Halt and Corporate Developments

Abattis Bioceuticals Corp. (the “Company” or “Abattis“) (CSE:ATT) (ATTBF) announces the following updates on recent developments related to Abattis since the trading of the Company’s common shares on the Canadian Stock Exchange (the “CSE”) was halted on February 4, 2019 (the “Halt”). Since the Halt, the Company filed its audited annual financial statements and management discussion and analysis on August 8, 2019. Following this, on August 16, 2019, the Company filed its interim financial statements and management discussion and analysis for the first quarter ended December 31, 2018 and second quarter ended March 31, 2019.
Posted: November 8, 2019, 10:00 pm

Abattis Completes Year End Audit and Provides Corporate Update

Abattis Bioceuticals Corp (the “Company” or “Abattis”) (ATT.CN) (ATTBF) announces the filing of its annual financial statements for the year ended September 30, 2018 and is pleased to provide the following comprehensive update on recent developments related to Abattis since the trading of the Company’s common shares (each, a “Share”) was halted on the Canadian Securities Exchange (“CSE”) on February 4, 2019. After a long process, the Company has finally filed its annual financial statements, the related management discussion and analysis and the certification of the annual filings for the year ended September 30, 2018 (the “Annual Filings”).
Posted: August 9, 2019, 5:35 pm